Plus Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview

Cerenome

28/02/2025 15:03

Plus Therapeutics Inc PSTV.OQ PSTV.O is expected to show a rise in quarterly revenue when it reports  results on March 3 (estimated) for the period ending December 31 2024

The Austin Texas-based  company is expected to report a 48.9% increase in revenue to $1.955 million from $1.31 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Plus Therapeutics Inc is for a loss of 39 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Plus Therapeutics Inc is $9.00​, above​ its last closing price of $0.68. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.51
-0.56
-0.37
Beat
34.2
Jun. 30 2024
-0.46
-0.53
-0.56
Missed
-5.7
Mar. 31 2024
-1.08
-1.09
-0.75
Beat
31.2​
Dec. 31 2023
-0.83
-1.07
-0.84
Beat
21.7
​​Sep. 30 2023
-1.02
-1.12
-1.00
Beat
10.9
Jun. 30 2023
-1.93
-1.91
-0.59
Beat
69.2​
Mar. 31 2023
-1.91
-1.90
-2.10
Missed
-10.5
Dec. 31 2022
-1.50
-1.80
-3.30
Missed
-83.3

This summary was machine generated February 28 at 15:02 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)